Gilead’s Covid-19 Drug is Mediocre. It Will Be a Blockbuster Anyway.

Health
By BY KATIE THOMAS from NYT Health https://ift.tt/34BnUum
via IFTTT your-feed-science, Coronavirus (2019-nCoV), Drugs (Pharmaceuticals), Remdesivir (Drug), Research, Company Reports Gilead Sciences said Wednesday that remdesivir, which has been authorized for emergency use since the spring, brought in $873 million in revenues so far this year.

Comments

Post a Comment

Popular posts from this blog

U.S. Quietly Drafts Plan to End Program That Saved Millions From AIDS

Image
Health By Stephanie Nolen from NYT Health https://ift.tt/FgKDG7N via IFTTT Acquired Immune Deficiency Syndrome, Developing Countries, United States Politics and Government, Medicine and Health, Foreign Aid, Disease Rates, Politics and Government, Layoffs and Job Reductions, Epidemics, Rationing and Allocation of Resources, Drugs (Pharmaceuticals) PEPFAR, the campaign to end H.I.V. globally, would morph into an effort to detect disease outbreaks and sell American products, according to documents obtained by The Times.
Read more

The Jarring Contradiction at the Heart of Kennedy’s Agenda

Image
Health By Benjamin Mueller and Dani Blum from NYT Health https://ift.tt/glFoDjr via IFTTT United States Politics and Government, Diet and Nutrition, Regulation and Deregulation of Industry, Food, Hazardous and Toxic Substances, Chemicals, Vaccination and Immunization, Rumors and Misinformation, Pesticides, Agriculture and Farming, Drugs (Pharmaceuticals), Food Contamination and Poisoning, Environment The health secretary has begun a full-on assault against vaccines but has taken a more restrained approach to pesticides and unhealthy foods, also MAHA priorities.
Read more